WallStSmart

Inspire Medical Systems Inc (INSP)vsNovartis AG ADR (NVS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 6208% more annual revenue ($56.69B vs $898.74M). NVS leads profitability with a 22.5% profit margin vs 15.0%. INSP trades at a lower P/E of 14.7x. NVS earns a higher WallStSmart Score of 51/100 (C-).

INSP

Buy

51

out of 100

Grade: C-

Growth: 7.3Profit: 6.0Value: 7.7Quality: 9.0
Piotroski: 5/9Altman Z: 5.38

NVS

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 9.0Value: 3.3Quality: 4.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

INSPUndervalued (+84.2%)

Margin of Safety

+84.2%

Fair Value

$431.37

Current Price

$73.00

$358.37 discount

UndervaluedFair: $431.37Overvalued
NVSSignificantly Overvalued (-47.0%)

Margin of Safety

-47.0%

Fair Value

$93.29

Current Price

$137.16

$43.87 premium

UndervaluedFair: $93.29Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INSP5 strengths · Avg: 9.2/10
EPS GrowthGrowth
308.4%10/10

Earnings expanding 308.4% YoY

Debt/EquityHealth
0.0410/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
5.3810/10

Safe zone — low bankruptcy risk

P/E RatioValuation
14.7x8/10

Attractively priced relative to earnings

Price/BookValuation
2.6x8/10

Reasonable price relative to book value

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$260.70B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
30.7%10/10

Every $100 of equity generates 31 in profit

Operating MarginProfitability
34.6%10/10

Strong operational efficiency at 34.6%

Profit MarginProfitability
22.5%9/10

Keeps 23 of every $100 in revenue as profit

Free Cash FlowQuality
$5.57B8/10

Generating 5.6B in free cash flow

Areas to Watch

INSP3 concerns · Avg: 2.0/10
Market CapQuality
$1.92B3/10

Smaller company, higher risk/reward

Revenue GrowthGrowth
-7.6%2/10

Revenue declined 7.6%

Operating MarginProfitability
-0.3%1/10

Operating margin of -0.3%

NVS4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
0.8%4/10

0.8% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Debt/EquityHealth
1.183/10

Elevated debt levels

PEG RatioValuation
3.222/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : INSP

The strongest argument for INSP centers on EPS Growth, Debt/Equity, Altman Z-Score.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.

Bear Case : INSP

The primary concerns for INSP are Market Cap, Revenue Growth, Operating Margin.

Bear Case : NVS

The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.

Key Dynamics to Monitor

INSP profiles as a declining stock while NVS is a value play — different risk/reward profiles.

INSP carries more volatility with a beta of 0.70 — expect wider price swings.

NVS is growing revenue faster at 0.8% — sustainability is the question.

NVS generates stronger free cash flow (5.6B), providing more financial flexibility.

Bottom Line

INSP scores higher overall (51/100 vs 51/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Inspire Medical Systems Inc

HEALTHCARE · MEDICAL DEVICES · USA

Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and Europe. The company is headquartered in Golden Valley, Minnesota.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?